CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 2,511 enrolled
Drug / intervention
Etanerceptdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00322439
NCT00322439N/ACompleted

Observational Post-Marketing Safety Surveillance Registry of Enbrel (Etanercept) for Treatment of Psoriasis

Amgen·observational·Posted May 8, 2006·Updated Jun 28, 2018

In Brief

An observational study evaluating Etanercept for Psoriasis. Completed, enrolled 2,511 participants.

Detailed Summary

This is an observational safety study tracking psoriasis patients on etanercept (Enbrel) for 5 years.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis
Countries--
Collaborators--

Timeline

N/ACompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMay 8, 2006
Enrollment StartMay 1, 2006
Primary CompletionDec 11, 2012
Study CompletionFeb 8, 2013
TodayJul 2, 2026
Enrollment to primary: 6.6 yearsPosted 20.2 years ago

Interventions

Etanerceptdrug

Observational study - no drug administered